227 related articles for article (PubMed ID: 34935773)
1. [Hyperkalemia in heart failure: etiology, epidemiology and prognosis].
Romani S; Sinagra G
G Ital Cardiol (Rome); 2021 Dec; 22(12 Suppl 1):e3-e7. PubMed ID: 34935773
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
[TBL] [Abstract][Full Text] [Related]
3. Optimally managing hyperkalemia in patients with cardiorenal syndrome.
Wang AY
Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii36-iii44. PubMed ID: 31800079
[TBL] [Abstract][Full Text] [Related]
4. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
[TBL] [Abstract][Full Text] [Related]
6. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.
Silva-Cardoso J; Brito D; Frazão JM; Ferreira A; Bettencourt P; Branco P; Fonseca C
Heart Fail Rev; 2021 Jul; 26(4):891-896. PubMed ID: 33599908
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacology of hyperkalemia].
Rosano GMC
G Ital Cardiol (Rome); 2021 Dec; 22(12 Suppl 1):e8-e12. PubMed ID: 34935774
[TBL] [Abstract][Full Text] [Related]
8. Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.
Paolillo S; Basile C; Dell'Aversana S; Esposito I; Chirico A; Colella A; Esposito G; Santo MD; Fierro MF; Carbone F; Marzano F; Amato C; Gargiulo P; Perrone Filardi P
Eur J Intern Med; 2024 Jan; 119():109-117. PubMed ID: 37648583
[TBL] [Abstract][Full Text] [Related]
9. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
[TBL] [Abstract][Full Text] [Related]
10. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
[TBL] [Abstract][Full Text] [Related]
11. Hyperkalemia in heart failure: Foe or friend?
Rakisheva A; Marketou M; Klimenko A; Troyanova-Shchutskaia T; Vardas P
Clin Cardiol; 2020 Jul; 43(7):666-675. PubMed ID: 32445223
[TBL] [Abstract][Full Text] [Related]
12. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
Johnson M; Morrison FJ; McMahon G; Su M; Turchin A
Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
[TBL] [Abstract][Full Text] [Related]
14. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
[TBL] [Abstract][Full Text] [Related]
15. Hyperkalemia in the Hypertensive Patient.
Lakkis JI; Weir MR
Curr Cardiol Rep; 2018 Mar; 20(2):12. PubMed ID: 29492706
[TBL] [Abstract][Full Text] [Related]
16. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.
Desai NR; Rowan CG; Alvarez PJ; Fogli J; Toto RD
PLoS One; 2020; 15(1):e0226844. PubMed ID: 31910208
[TBL] [Abstract][Full Text] [Related]
17. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
Pitt B; Garza D
Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
[TBL] [Abstract][Full Text] [Related]
18. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
[TBL] [Abstract][Full Text] [Related]
19. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.
Kanda E; Rastogi A; Murohara T; Lesén E; Agiro A; Arnold M; Chen G; Yajima T; Järbrink K; Pollack CV
BMC Nephrol; 2023 Jan; 24(1):18. PubMed ID: 36658531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
